David Hollenback Selected Research

2-acylglycerophosphate acyltransferase

11/2006	Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
8/2006	Effect of lysophosphatidic acid acyltransferase-beta inhibition in acute leukemia.
7/2005	Induction of apoptosis using inhibitors of lysophosphatidic acid acyltransferase-beta and anti-CD20 monoclonal antibodies for treatment of human non-Hodgkin's lymphomas.
10/2003	Inhibition of lysophosphatidic acid acyltransferase beta disrupts proliferative and survival signals in normal cells and induces apoptosis of tumor cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David Hollenback Research Topics

Disease

5	Neoplasms (Cancer) 04/2014 - 10/2003
2	Fibrosis (Cirrhosis) 01/2022 - 10/2020
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 10/2020
2	Leukemia 11/2006 - 08/2006
1	Hypertriglyceridemia 01/2022
1	Alcoholic Fatty Liver 10/2020
1	Inflammation (Inflammations) 10/2020
1	Liver Diseases (Liver Disease) 10/2020
1	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 04/2014
1	Body Weight (Weight, Body) 04/2014
1	Congenital Generalized Lipodystrophy (Berardinelli-Seip Congenital Lipodystrophy) 08/2008
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 11/2006
1	Lymphoma (Lymphomas) 07/2005
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 07/2005
1	Carcinogenesis 10/2003

Drug/Important Bio-Agent (IBA)

4	2-acylglycerophosphate acyltransferaseIBA 11/2006 - 10/2003
2	Choline (Choline Chloride)IBA 01/2022 - 10/2020
2	LipidsIBA 01/2022 - 10/2020
2	CT-32228IBA 08/2006 - 07/2005
2	Protein Isoforms (Isoforms)IBA 08/2006 - 10/2003
1	saroglitazarIBA 01/2022
1	lanifibranorIBA 01/2022
1	firsocostatIBA 01/2022
1	seladelparIBA 01/2022
1	2- (2,6- dimethyl- 4- (3- (4- (methylthio)phenyl)- 3- oxo- 1- propenyl)phenoxyl)- 2- methylpropanoic acidIBA 01/2022
1	resmetiromIBA 01/2022
1	Thyroid Hormone Receptors beta (TR beta)IBA 01/2022
1	Acetyl-CoA CarboxylaseIBA 01/2022
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 01/2022
1	Fenofibrate (CiL)FDA LinkGeneric 01/2022
1	Diethylnitrosamine (N-Nitrosodiethylamine)IBA 10/2020
1	ProcollagenIBA 10/2020
1	Phosphotransferases (Kinase)IBA 04/2014
1	2- hydroxy- 1- (2- ((9- (4- methylcyclohexyl)- 9H- pyrido(4',3'- 4,5)pyrrolo(2,3- d)pyrimidin- 2- yl)amino)- 7,8- dihydro- 1,6- naphthyridin- 6(5H)- yl)ethanoneIBA 04/2014
1	LeptinIBA 08/2008
1	Pharmaceutical PreparationsIBA 11/2006
1	Imatinib Mesylate (Gleevec)FDA Link 11/2006
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 11/2006
1	EnzymesIBA 08/2006
1	Proteins (Proteins, Gene)FDA Link 08/2006
1	ThymidineIBA 07/2005
1	Monoclonal AntibodiesIBA 07/2005
1	CaspasesIBA 07/2005
1	DiaminesIBA 10/2003
1	Phosphatidic Acids (Phosphatidic Acid)IBA 10/2003
1	TriazinesIBA 10/2003

Therapy/Procedure

4	Therapeutics 01/2022 - 10/2003